<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02206685</url>
  </required_header>
  <id_info>
    <org_study_id>H32894</org_study_id>
    <nct_id>NCT02206685</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Single Intra-op Dose of Methadone Versus Placebo in Patients Undergoing Spine Surgery</brief_title>
  <official_title>A Randomized Blinded Prospective Trial Comparing Single Intraoperative Dose of Methadone Versus Placebo in Pediatric Patients Undergoing Spine Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scoliosis is a disease that involves lateral and/or rotational deformity of the spine and can&#xD;
      affect up to 4% of the population. Typically, surgery is considered when Cobb's angle, which&#xD;
      is a measurement used for evaluation of curves in scoliosis on an anterior-posterior&#xD;
      radiographic projection of the spine, is greater than 50 degrees in the thoracic region (40&#xD;
      degrees in the lumbar region) or when the curvature causes significant pain, or respiratory&#xD;
      and cardiovascular restriction. Patient undergoing this surgical correction experience severe&#xD;
      pain in the postoperative period and the management includes the use of opioid-based&#xD;
      patient-controlled analgesia (PCA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scoliosis is a disease that involves lateral and/or rotational deformity of the spine and can&#xD;
      affect up to 4% of the population. Typically, surgery is considered when Cobb's angle, which&#xD;
      is a measurement used for evaluation of curves in scoliosis on an anterior-posterior&#xD;
      radiographic projection of the spine, is greater than 50 degrees in the thoracic region (40&#xD;
      degrees in the lumbar region) or when the curvature causes significant pain, or respiratory&#xD;
      and cardiovascular restriction. Patient undergoing this surgical correction experience severe&#xD;
      pain in the postoperative period and the management includes the use of opioid-based&#xD;
      patient-controlled analgesia (PCA).&#xD;
&#xD;
      Methadone is an opioid with one of the longest elimination half-life and has been used as an&#xD;
      effective analgesic for acute, chronic, neuropathic, and cancer pain in adults, children, and&#xD;
      even neonates1-5. Its long duration of action and antagonism to the N-methyl-d-aspartate&#xD;
      receptor may decrease the need for PCA use in the postoperative period. Gourlay2 demonstrated&#xD;
      the effectiveness and utility of perioperative methadone including the advantages of longer&#xD;
      analgesia with no serious side effects of respiratory depression. A recent study by&#xD;
      Gottschalk2 in adult patients demonstrated a 50% reduction of postoperative opioids at 48&#xD;
      hours and lower pain scores after a single bolus of methadone before surgical incision.&#xD;
      However, a major weakness of the study is that patients did not receive equipotent&#xD;
      intraoperative opioids. In addition, the adolescent patient population will undergo a much&#xD;
      larger surgical incision with potential for greater postoperative pain. Despite this&#xD;
      potential benefit, methadone is seldom used in the perioperative setting. A more recent&#xD;
      pharmacokinetic study of methadone in adolescents undergoing spine surgery failed to show a&#xD;
      reduction in opioid consumption as it was powered to determine pharmacokinetics and not a&#xD;
      secondary endpoint of postoperative opioid consumption. An appropriately powered study is&#xD;
      still required to determine the efficacy of methadone in reducing postoperative pain after&#xD;
      spine surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">January 27, 2020</completion_date>
  <primary_completion_date type="Actual">January 27, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Usage</measure>
    <time_frame>Admission to PACU to 72 hours post-operative</time_frame>
    <description>Subjects were given access to Patient-Controlled Intravenous Opioid Administration (PCA) to manage their post-operative pain. The doses of morphine were calculated at at PACU, 24 hours, 48 hours and 72 hours respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>Admission to PACU to 72 hours post-operative</time_frame>
    <description>The FLACC scale or Face, Legs, Activity, Cry, Consolability scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2. The data reported here represents the mean difference in FLACC score by treatment group at PACU, 24 hours, 48 hours and 72 hours, respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Thoracolumbar Scoliosis</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive a 20 ml normal saline placebo infusion over 10 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Treatment group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>the control group will receive a 20 ml normal saline placebo infusion over 10 minutes</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Control Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age 10 - 17 years&#xD;
&#xD;
          2. Patients undergoing multilevel thoraco-lumbar spine surgery with instrumentation and&#xD;
             fusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Preoperative methadone therapy&#xD;
&#xD;
          2. Inability to use the PCA&#xD;
&#xD;
          3. Allergy to methadone or morphine&#xD;
&#xD;
          4. Morbid obesity with a body mass index &gt;36.0 kg/m2&#xD;
&#xD;
          5. Patients with chronic renal failure defined by serum creatinine &gt;2.0 mg/dL&#xD;
&#xD;
          6. Liver failure defined as a history of cirrhosis or fulminant hepatic failure&#xD;
&#xD;
          7. Preoperative congenital heart disease or arrhythmias&#xD;
&#xD;
          8. Patient refusal to participate in study&#xD;
&#xD;
          9. Pregnancy (It is standard of care for all post menarche female patients to undergo a&#xD;
             urine pregnancy test prior to surgery).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Nguyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003971. Review. Update in: Cochrane Database Syst Rev. 2017 Feb 08;2:CD003971.</citation>
    <PMID>17943808</PMID>
  </reference>
  <reference>
    <citation>Gourlay GK, Wilson PR, Glynn CJ. Pharmacodynamics and pharmacokinetics of methadone during the perioperative period. Anesthesiology. 1982 Dec;57(6):458-67.</citation>
    <PMID>6128949</PMID>
  </reference>
  <reference>
    <citation>Gottschalk A, Durieux ME, Nemergut EC. Intraoperative methadone improves postoperative pain control in patients undergoing complex spine surgery. Anesth Analg. 2011 Jan;112(1):218-23. doi: 10.1213/ANE.0b013e3181d8a095. Epub 2010 Apr 24.</citation>
    <PMID>20418538</PMID>
  </reference>
  <reference>
    <citation>Sharma A, Tallchief D, Blood J, Kim T, London A, Kharasch ED. Perioperative pharmacokinetics of methadone in adolescents. Anesthesiology. 2011 Dec;115(6):1153-61. doi: 10.1097/ALN.0b013e318238fec5.</citation>
    <PMID>22037641</PMID>
  </reference>
  <reference>
    <citation>Berde CB, Beyer JE, Bournaki MC, Levin CR, Sethna NF. Comparison of morphine and methadone for prevention of postoperative pain in 3- to 7-year-old children. J Pediatr. 1991 Jul;119(1 Pt 1):136-41.</citation>
    <PMID>2066846</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2014</study_first_posted>
  <results_first_submitted>December 28, 2020</results_first_submitted>
  <results_first_submitted_qc>January 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2021</results_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Kim Nguyen</investigator_full_name>
    <investigator_title>Pediatric Anesthesiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scoliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Methods of statistical analysis may be shared at study completion.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02206685/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.&#xD;
Methadone: The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>The control group will receive a 20 ml normal saline placebo infusion over 10 minutes&#xD;
Normal Saline: the control group will receive a 20 ml normal saline placebo infusion over 10 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Surgery cancelled/changed</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.&#xD;
Methadone: The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>The control group will receive a 20 ml normal saline placebo infusion over 10 minutes&#xD;
Normal Saline: the control group will receive a 20 ml normal saline placebo infusion over 10 minutes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.09" spread="1.69"/>
                    <measurement group_id="B2" value="14.33" spread="1.69"/>
                    <measurement group_id="B3" value="14.21" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.26" spread="12.72"/>
                    <measurement group_id="B2" value="53.95" spread="13.20"/>
                    <measurement group_id="B3" value="56.18" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160.64" spread="9.98"/>
                    <measurement group_id="B2" value="162.48" spread="8.07"/>
                    <measurement group_id="B3" value="161.53" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.45" spread="3.78"/>
                    <measurement group_id="B2" value="20.29" spread="3.89"/>
                    <measurement group_id="B3" value="21.41" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA Status</title>
          <description>The ASA (American Society of Anesthesiologists) physical status classification system is a system for assessing the fitness of patients before surgery.&#xD;
ASA I: A normal healthy patient ASA II: A patient with mild systemic disease ASA III: A patient with severe systemic disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Opioid Usage</title>
        <description>Subjects were given access to Patient-Controlled Intravenous Opioid Administration (PCA) to manage their post-operative pain. The doses of morphine were calculated at at PACU, 24 hours, 48 hours and 72 hours respectively.</description>
        <time_frame>Admission to PACU to 72 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.&#xD;
Methadone: The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group will receive a 20 ml normal saline placebo infusion over 10 minutes&#xD;
Normal Saline: the control group will receive a 20 ml normal saline placebo infusion over 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Usage</title>
          <description>Subjects were given access to Patient-Controlled Intravenous Opioid Administration (PCA) to manage their post-operative pain. The doses of morphine were calculated at at PACU, 24 hours, 48 hours and 72 hours respectively.</description>
          <units>mg/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PACU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.25" upper_limit="0.65"/>
                    <measurement group_id="O2" value="0.47" lower_limit="0.33" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.34" upper_limit="0.82"/>
                    <measurement group_id="O2" value="0.55" lower_limit="0.37" upper_limit="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.31" upper_limit="0.79"/>
                    <measurement group_id="O2" value="0.55" lower_limit="0.24" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="0" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores</title>
        <description>The FLACC scale or Face, Legs, Activity, Cry, Consolability scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2. The data reported here represents the mean difference in FLACC score by treatment group at PACU, 24 hours, 48 hours and 72 hours, respectively.</description>
        <time_frame>Admission to PACU to 72 hours post-operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.&#xD;
Methadone: The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group will receive a 20 ml normal saline placebo infusion over 10 minutes&#xD;
Normal Saline: the control group will receive a 20 ml normal saline placebo infusion over 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores</title>
          <description>The FLACC scale or Face, Legs, Activity, Cry, Consolability scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2. The data reported here represents the mean difference in FLACC score by treatment group at PACU, 24 hours, 48 hours and 72 hours, respectively.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PACU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.76"/>
                    <measurement group_id="O2" value="0.65" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.4"/>
                    <measurement group_id="O2" value="0.42" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.45"/>
                    <measurement group_id="O2" value="0.36" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.18"/>
                    <measurement group_id="O2" value="0.29" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At any time during hospitalization (Days 0 to 5)</time_frame>
      <desc>Side effects of Methadone versus Placebo group were assessed during the duration of the subject's hospitalization. Incidents were counted once per subject.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.&#xD;
Methadone: The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>The control group will receive a 20 ml normal saline placebo infusion over 10 minutes&#xD;
Normal Saline: the control group will receive a 20 ml normal saline placebo infusion over 10 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxemia (oxygen required)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kim P. Nguyen, MD, Principal Investigator</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>832-824-5907</phone>
      <email>kpnguyen@texaschildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

